Doxazosin
Modify Date: 2024-01-09 19:42:42
Doxazosin structure
|
Common Name | Doxazosin | ||
|---|---|---|---|---|
| CAS Number | 74191-85-8 | Molecular Weight | 451.48 | |
| Density | 1.371 g/cm3 | Boiling Point | 718ºC at 760 mmHg | |
| Molecular Formula | C23H25N5O5 | Melting Point | 289-290°C | |
| MSDS | N/A | Flash Point | 388ºC | |
Use of DoxazosinDoxazosin(UK 33274) is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors.Target: Adrenergic ReceptorDoxazosin is a long-lasting inhibitor of α1-adrenoceptors that is widely used to treat benign prostatic hyperplasia and lower urinary tract symptoms [1]. doxazosin may have a direct inhibitory effect on cholesterol synthesis independent of the LDL receptor. The inhibition of cholesterol synthesis by doxazosin may cause cells to compensate by upregulating the LDL receptor, thereby increasing the importation of lipoprotein cholesterol and reducing LDL cholesterol in the medium [2]. Doxazosin monotherapy was effective in eight of 12 patients (66.7%), and combined therapy with a beta-blocker was effective in 11 of 12 patients (91.7%). The mean pulse rate remained constant throughout therapy. Adverse reactions were minor and transient and occurred in only three patients. Urinary and plasma catecholamine levels tended to decrease or remained unchanged during doxazosin therapy [3].Clinical indications: Hypertension; Prostate hyperplasiaFDA Approved Date: February 22, 2005Toxicity: Symptoms of overdose include hypotension |
| Name | doxazosin |
|---|---|
| Synonym | More Synonyms |
| Description | Doxazosin(UK 33274) is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors.Target: Adrenergic ReceptorDoxazosin is a long-lasting inhibitor of α1-adrenoceptors that is widely used to treat benign prostatic hyperplasia and lower urinary tract symptoms [1]. doxazosin may have a direct inhibitory effect on cholesterol synthesis independent of the LDL receptor. The inhibition of cholesterol synthesis by doxazosin may cause cells to compensate by upregulating the LDL receptor, thereby increasing the importation of lipoprotein cholesterol and reducing LDL cholesterol in the medium [2]. Doxazosin monotherapy was effective in eight of 12 patients (66.7%), and combined therapy with a beta-blocker was effective in 11 of 12 patients (91.7%). The mean pulse rate remained constant throughout therapy. Adverse reactions were minor and transient and occurred in only three patients. Urinary and plasma catecholamine levels tended to decrease or remained unchanged during doxazosin therapy [3].Clinical indications: Hypertension; Prostate hyperplasiaFDA Approved Date: February 22, 2005Toxicity: Symptoms of overdose include hypotension |
|---|---|
| Related Catalog | |
| References |
| Density | 1.371 g/cm3 |
|---|---|
| Boiling Point | 718ºC at 760 mmHg |
| Melting Point | 289-290°C |
| Molecular Formula | C23H25N5O5 |
| Molecular Weight | 451.48 |
| Flash Point | 388ºC |
| PSA | 175.02000 |
| LogP | 2.88670 |
| Storage condition | -20℃ |
| Hazard Codes | T,Xi |
|---|---|
| Risk Phrases | R23/24/25:Toxic by inhalation, in contact with skin and if swallowed . R34:Causes burns. R40:Limited evidence of a carcinogenic effect. R43:May cause sensitization by skin contact. R36/37/38:Irritating to eyes, respiratory system and skin . R38:Irritating |
| Safety Phrases | S36/37-S37/39-S26-S36 |
| RIDADR | UN 1198 3/PG 3 |
| WGK Germany | 2 |
| RTECS | LP8925000 |
|
~81%
Doxazosin CAS#:74191-85-8 |
| Literature: Kumaraswamy; Das; Jena, Nivedita Organic Preparations and Procedures International, 2003 , vol. 35, # 6 p. 603 - 608 |
|
~%
Doxazosin CAS#:74191-85-8 |
| Literature: US2012/41199 A1, ; Page/Page column 7-8 ; |
|
~%
Doxazosin CAS#:74191-85-8 |
| Literature: Organic Preparations and Procedures International, , vol. 35, # 6 p. 603 - 608 |
|
~%
Doxazosin CAS#:74191-85-8 |
| Literature: Organic Preparations and Procedures International, , vol. 35, # 6 p. 603 - 608 |
|
~%
Doxazosin CAS#:74191-85-8 |
| Literature: US2012/41199 A1, ; |
![(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)(1H-imidazol-1-yl)methanone structure](https://image.chemsrc.com/caspic/209/1246188-97-5.png)
| Doxazosine [French] |
| 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazine |
| Doxazosinum |
| Normothen |
| Cardura |
| Doxazosina |
| Doxazosine |
| Cardura-1 |
| Cardura-2 |
| Cardura-4 |
| MFCD00800482 |
| 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazoline |
| [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone |